A selection of recent successful placements and new projects globally. Focus in the 1st quarter of 2021 has been mainly on AI/Digital, Animal Health, Synthetic Biology, Vaccines, Diagnostics, CNS Diseases, Infectious Diseases, Immuno-oncology, Rare Diseases, Ophthalmology, Regenerative Medicine and Contract Manufacturing.
EVENTS
20 April - 23 April
2021
NLSDays attract leading decision makers from biotech, pharma and medtech as well as finance, research, policy and regulatory authorities. This year in digital format, the topics and presenters will provide insight into the most recent trends in science and business. Join our team for this event in April.
Coulter Partners was very pleased to partner recently with OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer, to secure the appointment of Dr Allison Jeynes as non-executive Chair of the Board of Directors.EVENTS
12 May
2021
We are experiencing societal shift on a massive scale. A global pandemic, inequality and climate risk have expedited the need to operate differently, think differently and lead differently. Are you prepared to lead in the next normal? Join us and the AESC as we explore this question and more...
A selection of C-suite, board, strategic commercial, R&D, medical and technical executive appointments for the past six months. Global hiring continues strongly and we look forward to collaborating on future projects!EVENTS
17 May - 19 May
2021
What’s coming next from Europe’s academic and biotech leaders? Join our team for the 21st Bio€quity Europe as industry leaders debate this questions and identify where Europe will continue to provide global leadership in biopharma innovation.
At their first HR Leadership Forum of the year in January, Coulter Partners launched the HR & Talent Leadership Pulse. This survey is designed for senior HR and Talent leaders globally in Life Sciences, Healthcare and Digital Health. Please take part and help us build a comprehensive picture... Through 2020 we saw incredible transformations across organisations, with HR and Talent professionals leading the way. To support this community in 2021, Coulter Partners has created the pulse survey which will continue to run throughout the year and monitor developments. EVENTS
21 June - 22 June
2021
Coulter Partners was delighted to partner again recently with Optimapharm to secure the appointments of Walter Miller as Chief Finance Officer and Dr Charles Woler, M.D., Ph.D., as Non-Executive Director. Optimapharm is a contract research organization (CRO) managing clinical trials on behalf of leading biotech, pharma and medical devices companies in 27 countries across EMEA.
Global Life Sciences executive search specialist, Coulter Partners is delighted to announce continuing growth across the company in 2021. The London team expands with new Associates, Lucy Webb and Ana Delgado, Research Analysts, Jacob Taylor and Liam Fryer, and Director, Carina McEntire. In the US, Ayn Teigman is appointed Associate in New York and Irlanda Almendarez joins as Senior Research Associate in California. In Frankfurt, the team is strengthened with Sonia Keim, Associate and Katja Färber, Senior Research Associate.
Coulter Partners recently talked to Dr James Field, Chief Executive Officer and Founder of LabGenius about digital disruption and talent in drug discovery. He told us, "We’ve developed a protein engineering platform that tightly integrates synthetic biology, machine learning, robotic automation and next generation sequencing. To achieve this, we’ve built a 50-strong team of data scientists, software engineers, automation engineers, drug discovery experts, molecular biologists, synthetic biologists… the list goes on...Our greatest challenge is one of organisational engineering: how to structure diverse teams of scientists and engineers to create value at the confluence of so many disparate technologies."
Coulter Partners kicked off 2021 with the first HR Leadership Forum of the year. The Forum was set up in 2020 to bring together the HR community to discuss key topics and share experiences among peers. Topics included changes in talent behaviour, onboarding and retention, collaboration models in hybrid environments, management expectations and normalisation trends. The next forum will gather on 24 February...
The Association of Executive Search and Leadership Consultants (AESC), the standards-setting body for the executive search and leadership consulting profession worldwide, today announces 2021 officers and the appointments of three new Directors to its Global Board. Coulter Partners is delighted to announce Joe’s appointment to the Board, together with his promotion to Chair of the AESC Council of Europe and Africa.
A selection of recent successful placements and new projects globally. Focus in the 4th quarter of 2020 has been mainly on Rare diseases, Artificial Intelligence, Dental, Vaccines, P.O.C. Diagnostics, Gene therapy, Oncology, Cardiovascular, Women's health, Neurology, Animal health and Venture teams.
After a year like no other we are charging into 2021 with hope and energy! Coulter Partners is indebted to the many people risking their own wellbeing on the front line to help those in need, and we are also completely awed by the dedication and energy of the scientists worldwide, whose unstinting work is enabling us all to look forward to a better future. A HUGE THANK YOU to everyone we have worked with in 2020, whose adaptability and perseverance have been so invaluable in helping us achieve our mutual goals. As vaccines begin to roll out, we are sure that together we can overcome the challenges ahead and help build a future we can be proud of.
Coulter Partners was delighted to partner with ObsEva SA (NASDAQ: OBSV / SIX: OBSN) to secure the appointment of Brian O’Callaghan as Chief Executive Officer and member of the company’s Executive Committee, effective 1 December 2020. He will succeed Dr Ernest Loumaye and be proposed for election on ObsEva’s Board of Directors at the next company AGM. ObsEva SA is a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health
Global Life Sciences search specialist, Coulter Partners and BioInnovation Institute (BII), the international incubator in Denmark for research-based innovation and entrepreneurship, are delighted to announce a ground-breaking collaboration agreement. Coulter Partners has been engaged to provide support for BII across three workstreams; providing assessment, coaching and development for the CEOs of start-up businesses in BII’s portfolio under the Creation House Programme, hiring chairs and board directors to support these businesses and conducting executive search for their portfolio companies where needed.
Coulter Partners recently talked to Dr Cornelius Maas, Senior Investment Manager at SHS Capital about leadership hiring and Betterguards, a SHS portfolio company. Betterguards is pioneering smart technology to prevent joint injuries and Coulter Partners helped secure the appointment of their new CEO, Jocelyn Robiot.
A selection of recent successful placements and new projects globally. Focus in the third quarter has been on CGT, Vaccines, Immunology, Digital Health, Oncology, Infectious Diseases, CNS, Haematology, Regenerative Medicines and other areas.
A selection of C-suite, board, strategic commercial, R&D, medical and technical executive appointments for the past six months. Global hiring continues strongly and we look forward to working with you in the second half of the year!
Coulter Partners was very pleased to partner once again with Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, to secure the appointment of Jason A. Amello as Chief Financial Officer. Jason will be based in the U.S. and will support Saniona’s advancement of late-stage clinical trials with lead product candidate Tesomet in two rare eating disorders, hypothalamic obesity (HO) and Prader Willi Syndrome (PWS).
A selection of successful executive placements and new projects globally. Focus this quarter has been on Vaccines, Cell & Gene Therapy, Women's Health, AI, Genomics, Animal Health, Rare Diseases, Precision Medicine, Immuno-oncology and other areas. 
Coulter Partners recently talked to Tanja Dowe, Chief Executive Officer of Debiopharm Innovation Fund S.A. about digital disruption and talent in healthcare. "At CEO and C-suite level I look for authenticity, passion and values. Why is passion so important and perhaps more so in healthcare than in other industries? We need individuals who really want to solve some of the biggest societal problems - working together with end-users to improve global patient health." 
Coulter Partners recently talked to Cristina Duran, Chief Digital Health Officer in R&D for AstraZeneca about digital disruption and talent in healthcare. "In other industries such as banking or retail, a focus on customers has always been key to the success of digital transformation. For pharmaceuticals it is the same. We focus on the patient and listen to what they want or need. We put the patient at the centre, listening to feedback on their experience of a clinical trial, for instance – the good and the bad. We are working together with patients and physicians in all our disease areas of focus to clarify the potential health outcomes of different treatment pathways."
"Medopad rebrands as Huma as it expands offerings and acquires AI and wearable tech startups." -
Coulter Partners talked recently to Tamir Strauss, Head of Customer Solutions at Huma about digital disruption and talent in healthcare: "I think if regulators were able to combine the fundamental need to keep patients safe with the understanding that the world of software development is evolving rapidly, then innovation would explode across all areas of this industry."
Coulter Partners was delighted to partner once again with Albumedix, the world leader in recombinant human albumin (rAlb), to secure the appointment of Gregor Kawaletz as Chief Commercial Officer, as of June 1st, 2020. This announcement follows the recent appointment of Jonas Skjødt Møller as Chief Executive Officer of Albumedix and is part of the company’s global growth strategy. 
JOB HUNTING IN A PANDEMIC: To paraphrase the advice printed on the top of every one of those metal lids of Hellman's mayonnaise: "keep cool; do not freeze." Cute, but it turned out to be great advice, and a rule that I've reminded myself to follow whenever I've been faced with challenging situations.
Coulter Partners was very pleased to partner recently with Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, to secure the appointment of Rudolf Baumgartner, M.D., as Chief Medical Officer and Head of Clinical Development. Dr. Baumgartner brings more than 20 years of experience leading multiple pharmaceutical development programs from discovery through approval and launch, in both large and small pharmaceutical companies.
A selection of successful executive placements and new projects globally. Focus this quarter has been on Vaccines, Immunology, Gene Therapy, AI, CNS, Medical Implants, Diagnostics, Regenerative Medicine, Oncology and other areas.